Floatz logo

Chimeric Antigen Receptor Modified T Cells Infusion

B Cell Lymphoma

The First Affiliated Hospital of Soochow UniversityCell therapyPhase 2/3Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB
VINCRISTINE SULFATE
The First Affiliated Hospital of Soochow University
Phase 4BB
Cart-19 And 20 Cells
Henan Cancer Hospital
Phase 2BB
Cart-19 Cells
Shenzhen BinDeBio Ltd.
Phase 2/3BB
Sonrotoclax
BeOne Medicines
Phase 3B

View all 50 →

Same molecule, other indications

Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:

Non Hodgkin LymphomaDormant
BB
Indicative ·
67 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
66 / 100
View asset →
Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)Dormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →